Related Experiment Video
Updated: Dec 2, 2025

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
Published on: January 7, 2019
Biological Relevance of RGD-Integrin Subtype-Specific Ligands in Cancer
Saidu Sani1,2, Mélissa Messe1,3, Quentin Fuchs1
1Laboratoire de Bioimagerie et Pathologies (LBP), UMR CNRS 7021, Institut Thématique Interdisciplinaire InnoVec, Université de Strasbourg, Faculté de Pharmacie, 74 route du, Rhin, CS 60024, 67401, Illkirch Cedex, France.
Abstract:
Integrins are heterodimeric transmembrane proteins able to connect cells with the micro-environment. They represent a family of receptors involved in almost all the hallmarks of cancer. Integrins recognizing the Arg-Gly-Asp (RGD) peptide in their natural extracellular matrix ligands have been particularly investigated as tumoral therapeutic targets. In the last 30 years, intense research has been dedicated to designing specific RGD-like ligands able to discriminate selectively the different RGD-recognizing integrins. Chemists' efforts have led to the proposition of modified peptide or peptidomimetic libraries to be used for tumor targeting and/or tumor imaging. Here we review, from the biological point of view, the rationale underlying the need to clearly delineate each RGD-integrin subtype by selective tools. We describe the complex roles of RGD-integrins (mainly the most studied αvβ3 and α5β1 integrins) in tumors, the steps towards selective ligands and the current usefulness of such ligands. Although the impact of integrins in cancer is well acknowledged, the biological characteristics of each integrin subtype in a specific tumor are far from being completely resolved. Selective ligands might help us to reconsider integrins as therapeutic targets in specific clinical settings.
Insights
Targeting cancer involves understanding integrins, which are cell receptors. Developing selective Arg-Gly-Asp (RGD) ligands is crucial for precisely targeting RGD-integrins like αvβ3 and α5β1 in tumors for better therapies.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- Integrins are transmembrane receptors mediating cell-extracellular matrix interactions.
- These receptors are implicated in numerous cancer hallmarks.
- Integrins recognizing the Arg-Gly-Asp (RGD) motif are key therapeutic targets.
Purpose of the Study:
- To review the biological rationale for developing selective RGD-integrin ligands.
- To discuss the complex roles of RGD-integrins in tumors.
- To evaluate the current utility of selective ligands in cancer research.
Main Methods:
- Literature review focusing on the biological aspects of RGD-integrins in cancer.
- Analysis of the development of selective RGD-like ligands.
- Discussion of the roles of αvβ3 and α5β1 integrins in tumor progression.
Main Results:
- Selective targeting of RGD-integrin subtypes is necessary due to their diverse roles in cancer.
- Significant efforts have been made in designing specific RGD-mimetic ligands.
- The biological characteristics of each integrin subtype in specific tumors remain incompletely understood.
Conclusions:
- Selective ligands are essential tools for dissecting the functions of individual RGD-integrins in cancer.
- Further research into integrin subtype-specific roles could refine their use as therapeutic targets.
- Targeting specific integrins offers potential for novel cancer therapies.
Related Concept Videos
Activation of Integrins
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
Integrins
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
Selectins
Intracellular Signaling Affects Focal Adhesions
Some...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Mitogens and the Cell Cycle

